How to buy I-Mab stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy I-Mab stock

Own I-Mab stock in just a few minutes.

I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 185 staff and has a market cap (total outstanding shares value) of USD0.00.

How to buy shares in I-Mab

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for I-Mab. Find the stock by name or ticker symbol: IMAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until I-Mab reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of I-Mab, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of I-Mab. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

I-Mab share price

Use our graph to track the performance of IMAB stocks over time.

I-Mab shares at a glance

Information last updated 2021-03-24.
52-week rangeUSD$11.28 - USD$65.94
50-day moving average USD$56.59
200-day moving average USD$45.68
Wall St. target priceUSD$76.82
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.70

Buy I-Mab shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy I-Mab stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

I-Mab financials

Gross profit TTM USD$30 million
Return on assets TTM -27.35%
Return on equity TTM -36.54%
Profit margin 0%
Book value N/A
Market capitalisation USD$3.3 billion

TTM: trailing 12 months

Shorting I-Mab shares

There are currently 578,034 I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 19% down from 713,318 last month.

There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.

I-Mab's "short interest ratio" (SIR)

I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 334123.69942197). I-Mab's SIR currently stands at 1.73. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 1730 shares are currently held short.

However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.

Find out more about how you can short I-Mab stock.

I-Mab share dividends

We're not expecting I-Mab to pay a dividend over the next 12 months.

I-Mab overview

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company's product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site